Press Releases

Investors

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Pharmaceuticals to Webcast Fiscal 2018 Second Quarter Results
PASADENA, Calif. --(BUSINESS WIRE)--Apr. 24, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 8, 2018 , at 4:30 p.m. EDT to discuss its financial results for the fiscal 2018 second quarter ended March 31, 2018 .
View HTML
Toggle Summary Arrowhead Pharmaceuticals Presents ARC-520 Clinical Data at The International Liver Congress™
PASADENA, Calif. --(BUSINESS WIRE)--Apr. 11, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the presentation of clinical data on ARC-520, the company’s prior generation investigational medicine for the treatment of chronic hepatitis B infection, at The International Liver
View HTML
Toggle Summary Arrowhead Pharmaceuticals Announces Multiple Presentations at The International Liver Congress™
PASADENA, Calif. --(BUSINESS WIRE)--Mar. 28, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will present clinical and pre-clinical data on the company’s investigational medicines for the treatment of chronic hepatitis B infection (ARC-520 and ARO-HBV) and liver disease
View HTML
Toggle Summary Arrowhead Begins Dosing in Phase 1/2 Study of ARO-HBV for Treatment of Chronic Hepatitis B
PASADENA, Calif. --(BUSINESS WIRE)--Mar. 27, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2 clinical study of ARO-HBV, which is being developed as a potentially curative therapy for patients with chronic hepatitis B virus
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
PASADENA, Calif. --(BUSINESS WIRE)--Mar. 20, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on March 16, 2018 , the Board of Directors approved "inducement" grants to six new employees under Rule 5635(c)(4) of
View HTML
Toggle Summary Arrowhead Begins Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
PASADENA, Calif. --(BUSINESS WIRE)--Mar. 12, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1 clinical study of ARO-AAT, which is being developed as treatment for a rare genetic liver disease associated with alpha-1 antitrypsin
View HTML
Toggle Summary Arrowhead to Present at Barclays Global Healthcare Conference 2018
PASADENA, Calif. --(BUSINESS WIRE)--Mar. 6, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the company will make a presentation at the following upcoming event: Barclays Global Healthcare Conference – Miami , March 13 , at 1:35 p.m.
View HTML
Toggle Summary Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has received approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) and from the local Ethics Committee to proceed with a first-in-human study of ARO-AAT, which
View HTML
Toggle Summary Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
PASADENA, Calif. --(BUSINESS WIRE)--Feb. 22, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has received approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) and from the local Ethics Committee to proceed with a first-in-human study of
View HTML
Toggle Summary Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the United States Food and Drug Administration (FDA) has granted orphan drug designation to ARO-AAT, Arrowhead's second-generation investigational medicine for the treatment of a rare genetic liver
View HTML